Most patients with hepatocellular carcinoma (HCC) present with advanced disease and therefore have only limited therapeutic options. Advancements in screening and surveillance have allowed more patients to be identified and diagnosed with earlier-stage disease, increasing their therapeutic options. New research into non-surgical treatment modalities offers exciting prospects of tumor eradication and disease control.
Deaths associated with colorectal cancer are most frequently related to metastatic disease to the liver. New treatment modalities have provided novel opportunities which previously did not exist for the management of this disease.
Many patients with pancreatic adenocarcinoma are not eligible for surgical resection due to the advanced nature of their disease. Those patients who undergo surgical resection have a high chance of recurrence within the first two years after resection and their overall survival is poor. Treatment modalities are rapidly evolving to combat the high mortality of this disease.
This program will provide a comprehensive review and update on the state-of-the-art management of HCC, metastatic liver tumors, and pancreatobiliary malignancies to include current surveillance, diagnostic and therapeutic guidelines in managing these patients by utilizing a multimodality approach of combining both non-surgical and surgical locoregional therapeutic options in order to provide the best supportive care of these patients and achieve optimal outcomes.
This activity is designed for healthcare providers involved in the screening, diagnosis, evaluation, management, prevention, and treatment of patients with HCC, metastatic liver tumors, and pancreatobiliary malignancies.
Provided by Rutgers, New Jersey Medical School, Department of Radiology, Division of Interventional Radiology and Department of Surgery, Division of Surgical Oncology
© 2018, Rutgers, The State University of New Jersey. All rights reserved.
185 South Orange Avenue, Newark, New Jersey 07103